$85.00Original price was: $85.00.$46.00Current price is: $46.00.
Ipamorelin is a short peptide sequence capable of binding to the ghrelin/growth hormone secretagogue receptor. It is one of the most selective growth hormone (GH) secretagogues known and has been shown in laboratory studies to have no effect on ACTH, prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, or cortisol release . Given its high level of specificity, ipamorelin has been of interest in research both as a therapeutic in and of itself as well as a model peptide for understanding how selectivity in GH receptor binding is achieved. Its presence plays a key role in the overall growth and repair of musculoskeletal tissue.
Ipamorelin is commonly dosed one to two times daily, depending on goals such as growth hormone stimulation, recovery, fat loss, or anti-aging. A standard starting dose is 100 mcg (0.1 ml) administered once daily before bed. If well tolerated, the dose may be increased to 200 mcg (0.2 ml) once or twice daily, typically pre-bed and optionally pre-workout or first thing in the morning.
A typical escalation protocol may look like the following:
Week 1–2: Start with 100 mcg (0.1 ml) once daily at night
Week 3–4: Increase to 200 mcg (0.2 ml) once daily
Week 5 and onward: Consider 200 mcg twice daily (0.2 ml in the morning + 0.2 ml at night), based on response and recovery goals
Doses may be maintained for 8–12 weeks, followed by a rest or cycling phase. The peptide is best administered subcutaneously into the lower abdomen or thigh, rotating sites to minimize irritation.
Each 10ml vial provides 10mg of Ipamorelin, allowing for:
Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It is part of the GHRP (Growth Hormone Releasing Peptide) family, known for stimulating the body’s natural production of growth hormone (GH) without significantly affecting cortisol or prolactin levels.
Ipamorelin stands out for its clean pharmacological profile, low risk of side effects, and high receptor selectivity. It mimics the ghrelin peptide by binding to GHSR-1a receptors in the pituitary and hypothalamus, leading to endogenous GH release and a cascade of regenerative, anabolic, and metabolic benefits.
Ipamorelin works by binding to the ghrelin (GHSR-1a) receptor, stimulating the release of growth hormone (GH) from the anterior pituitary. It does not directly replace GH, but instead signals the body to enhance its natural pulsatile secretion.
Key pharmacological actions include:
Increased GH pulse amplitude
Minimal impact on ACTH, cortisol, or prolactin levels
Improved IGF-1 production via liver stimulation
Enhanced protein synthesis and fat metabolism
Preservation of natural GH feedback mechanisms
This makes Ipamorelin ideal for long-term use, with low risk of endocrine disruption.
Due to a lack of human safety data and potential hormonal effects, Ipamorelin is not recommended during pregnancy or lactation. Animal studies have not conclusively demonstrated teratogenic effects, but use during these phases should be avoided.
Ipamorelin is not approved for pediatric use. While it may stimulate GH in GH-deficient children, it should only be used in a clinical setting under specialist care. Off-label or unsupervised pediatric use is contraindicated.
Ipamorelin is not approved by the FDA as a prescription medication. It remains a research compound and investigational peptide, though widely used in compounding and functional medicine settings for its regenerative and metabolic potential.
